Successful epoprostenol withdrawal and termination with an aid of the exercise stress test in pulmonary arterial hypertension.

Continuous infusion of intravenous epoprostenol (EPO) improves exercise capacity and survival in pulmonary arterial hypertension (PAH); however, it is associated with side effects. This study aimed to describe our experience on safe EPO withdrawal with the aid of an exercise stress test. This retrospective review included patients with PAH who were successfully withdrawn from EPO. Haemodynamic data were obtained before EPO administration, at withdrawal, and after discontinuation. After the mean pulmonary arterial pressure (mPAP) decreased to <25 mmHg for at least 1 year, an exercise test under right heart catheterisation was performed. If exercise pulmonary hypertension was not record (mPAP - cardiac output slope < 3), EPO was withdrawn. Of the 99 patients who received EPO, ten were identified as having undergone withdrawal or termination. mPAP decreased from 61 (54-71) mmHg before treatment to 19 (17-21) mmHg before withdrawal and remained unchanged, at 19 (14-23) mmHg, 1 year after EPO discontinuation. After a median follow-up of 32 months, all the patients survived. Patients with PAH who recovered their normal haemodynamic function were safely withdrawn from EPO with the aid of an exercise stress test. Copyright © 2021 Elsevier B.V. All rights reserved.

Citation

Kaori Takeuchi, Ayumi Goda, Junnosuke Ito, Hanako Kikuchi, Takumi Inami, Takashi Kohno, Kyoko Soejima, Toru Satoh. Successful epoprostenol withdrawal and termination with an aid of the exercise stress test in pulmonary arterial hypertension. International journal of cardiology. 2022 Jan 01;346:80-85

Mesh Tags

Substances

PMID: 34798203

search → result